Insulin aspart and insulin lispro: Difference between revisions
Jump to navigation
Jump to search
NCLEX nursing pharmacology monographs — batch import |
Add medication infobox (Drugbox) to monographs |
||
| Line 1: | Line 1: | ||
{{Drugbox | |||
| name = Insulin aspart and insulin lispro | |||
| brand = NovoLog, Humalog | |||
| therapeutic = Antidiabetic | |||
| pharmacologic = Rapid-acting insulin analogs | |||
| onset = Onset 10 to 20 minutes; peak 1 to 3 hours; duration 3 to 5 hours. | |||
| halflife = Monitor glucose, not levels. | |||
| routes = SubQ | |||
| highalert = <span style="color:#b00020;">'''Yes'''</span> | |||
| blackbox = None | |||
| antidote = Glucose or glucagon. | |||
| pregnancy = Insulin preferred. | |||
}} | |||
<div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | <div style="border-left:4px solid #3f6f5b;background:#f3f6f4;padding:8px 12px;margin-bottom:12px;font-size:0.95em;"> | ||
''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ''Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and '''must be verified against current manufacturer labeling before clinical use'''. This is educational content, not prescribing guidance.'' | ||
Latest revision as of 16:09, 17 June 2026
| Drug monograph · NCLEX study reference | |
| Trade names | NovoLog, Humalog |
|---|---|
| Therapeutic class | Antidiabetic |
| Pharmacologic class | Rapid-acting insulin analogs |
| Onset / peak / duration | Onset 10 to 20 minutes; peak 1 to 3 hours; duration 3 to 5 hours. |
| Half-life / level | Monitor glucose, not levels. |
| Routes | SubQ |
| High-alert (ISMP) | Yes |
| Black box warning | None |
| Antidote / reversal | Glucose or glucagon. |
| Pregnancy / lactation | Insulin preferred. |
Nursing pharmacology study reference (NCLEX-style monograph). Numeric values are standard teaching ranges for study and must be verified against current manufacturer labeling before clinical use. This is educational content, not prescribing guidance.
Insulin aspart and insulin lispro (brand names NovoLog, Humalog) — Antidiabetic; Rapid-acting insulin analogs.
Identification
- Therapeutic class: Antidiabetic.
- Pharmacologic class: Rapid-acting insulin analogs.
Pharmacology
- Mechanism of action: Rapid mealtime (bolus) glucose control.
- Onset / peak / duration: Onset 10 to 20 minutes; peak 1 to 3 hours; duration 3 to 5 hours.
- Half-life / therapeutic level: Monitor glucose, not levels.
Clinical use
- Indications: Mealtime coverage, correction dosing, insulin pumps, IV in critical care (aspart, regular more common IV).
- Usual dose, route, frequency: SubQ within 15 minutes before or just after meals.
- Maximum dose / adjustments: Individualized; match to carbohydrate intake.
Safety
- Contraindications: Hypoglycemia, hypersensitivity.
- Black box warning: None.
- Interactions: Same insulin interactions.
- Pregnancy / lactation: Insulin preferred.
- High-alert: Yes.
Adverse effects
- Common side effects: Hypoglycemia, injection reactions, weight gain.
- Serious effects to report: Severe hypoglycemia.
- Antidote / reversal: Glucose or glucagon.
Nursing process
- Assessment before administration: Blood glucose and that food is available.
- Interventions during therapy: Ensure the patient eats; can mix with NPH (draw clear before cloudy); double-check per policy.
- Monitor: Blood glucose, A1c, mealtime intake.
- Evaluation / expected outcome: Controlled postmeal glucose.
Patient teaching
- Patient teaching: Give just before eating; never delay the meal.
- Notify provider if: Frequent lows.
- Administration tips: SubQ; rotate sites; time to meals.